Compare Inovio Pharmaceuticals Inc (INO) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nomura Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Nomura Holdings Inc trades at $9.73 (market cap $27.46B). The key difference: Nomura Holdings Inc is far larger — about 307.6× Inovio Pharmaceuticals Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NMR | |
|---|---|---|
Market Cap | $89.27M | $27.46B |
Sector | Health | Financials |
52-Week High | $2.87 | $10.04 |
52-Week Low | $1.05 | $6.39 |
Enterprise Value | $60.28M | — |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Nomura Holdings (NMR) trades at $9.395, down 0.05% on the day, with a bullish technical signal from moving averages. The company reported record annual net income of $340.74 billion for 2025, with a net income margin of 20.49%, while revenue grew to $1.66 trillion. Recent news highlights strong wholesale revenue momentum and strategic acquisitions, including a U.S. fund management expansion. The stock shows a P/E of 12.78 and P/B of 1.2, indicating potential value relative to earnings.
The outlook for NMR is supported by earnings growth and strategic initiatives, but risks include volatile cash flows and rising debt levels. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism. Further upside depends on sustained profitability and successful integration of recent acquisitions amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
